source
- FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impactThe FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol. The drug arrives as new clinical guidelines encou…
- NIH joins Trump’s $5B AI Genesis Mission to boost biomedical researchThe U.S. Department of Health and Human Services announced that the National Institutes of Health will take part in the President’s Genesis Mission, a $5 billion AI-driven effort. The initiative a…